Trust Signals
Key Takeaways
- Tirzepatide is an FDA-approved new drug (Mounjaro approved May 2022, Zepbound approved November 2023), not an unscheduled novel compound, so selling it as a "research chemical" violates the Federal Food, Drug, and Cosmetic Act.
- The FDA declared the tirzepatide shortage resolved in December 2024, closing the shortage-based compounding exemption that had briefly allowed 503A and 503B facilities to prepare it legally.
- Eli Lilly has actively pursued legal action against unauthorized compounders and vendors, creating direct patent and trade-secret liability for any seller outside the licensed pharmacy chain.
- Research chemical vendors that continued selling tirzepatide after the shortage closure faced FDA warning letter risk, which the agency has used against GLP-1 peptide suppliers.
- For legitimate preclinical research, tirzepatide API is obtainable through licensed chemical suppliers under proper material transfer agreements; for clinical use, a prescription through a licensed pharmacy is the only compliant path.
Why Did Peptide Sciences Stop Selling Tirzepatide?
Table of Contents
- What is tirzepatide and why does its legal status matter?
- What specific laws made the sale problematic?
- What was the shortage exemption and when did it end?
- What role did Eli Lilly's IP enforcement play?
- Evidence ledger: claims and their basis
- What most pages get wrong about "research use only" labels
- How the chemistry and formulation raised additional red flags
- Honest comparison: research vendor vs. licensed pharmacy vs. compounding pharmacy
- Operational guide: how to read a COA and what it tells you
- FAQ
- Sources
What Is Tirzepatide and Why Does Its Legal Status Matter?
Tirzepatide is a 39-amino-acid synthetic peptide that acts as a dual agonist at both the GLP-1 receptor and the GIP receptor. Eli Lilly developed it under the brand names Mounjaro (type 2 diabetes, FDA-approved May 2022) and Zepbound (chronic weight management, FDA-approved November 2023). That approval status is the entire legal pivot point.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Before approval, a structurally novel peptide occupies a regulatory gray zone. Vendors could argue that selling it for "research purposes only" did not constitute selling a drug. The moment the FDA approves a specific molecular entity, that argument collapses. Tirzepatide became a drug under 21 U.S.C. 321(g)(1) on the day of its first NDA approval, and any entity selling it outside of the approved distribution chain became subject to FDCA enforcement.
What Specific Laws Made the Sale Problematic?
Three intersecting legal frameworks converged on research chemical vendors selling tirzepatide:
1. FDCA Section 301 prohibitions. The Federal Food, Drug, and Cosmetic Act prohibits the introduction of an unapproved new drug into interstate commerce. Once tirzepatide received NDA approval, any version sold outside that approval pathway is by definition an unapproved new drug (or an adulterated/misbranded version of an approved drug).
2. Drug Quality and Security Act (DQSA) and 503A/503B compounding rules. The DQSA created two compounding tracks. 503A pharmacies compound for individual patients with a prescription. 503B outsourcing facilities compound in larger quantities and are FDA-registered. Neither track covers a research chemical vendor with no pharmacist, no patient, and no prescription. Selling tirzepatide as a raw peptide for reconstitution does not fit either track at all.
3. Patent and trade-secret law. Eli Lilly holds patents covering the tirzepatide molecule, formulation, and therapeutic use. Manufacturing or selling the compound without a license is patent infringement under 35 U.S.C. 271. Lilly has not licensed any research chemical vendor.
What Was the Shortage Exemption and When Did It End?
From roughly 2022 through late 2024, tirzepatide was on the FDA's drug shortage list. Under 21 U.S.C. 503A and 503B, compounding pharmacies may prepare a drug that appears on the FDA shortage list even if it is an approved product, under certain conditions.
On December 19, 2024, the FDA announced it had determined the tirzepatide shortage was resolved and updated the shortage database accordingly. The FDA's subsequent guidance gave 503A pharmacies a wind-down period and gave 503B outsourcing facilities a separate, somewhat longer compliance window, but both windows were finite and have since closed or are closing.
Research chemical vendors were never operating inside this exemption to begin with. The shortage exemption applied to licensed compounding pharmacies dispensing to patients with prescriptions. A vendor selling vials of lyophilized tirzepatide powder to anonymous internet buyers with no prescription was never within the exemption's scope, even during the shortage period.
What Role Did Eli Lilly's IP Enforcement Play?
Eli Lilly filed suit in multiple federal courts against compounding pharmacies producing tirzepatide, arguing both patent infringement and trade dress violations. These suits are public record in federal court dockets and received reporting in pharmaceutical trade press throughout 2024 and 2025.
While Peptide Sciences has not publicly disclosed whether it received a direct cease-and-desist letter from Lilly, the legal exposure from even a single such communication is severe enough that most small vendors would remove the product preemptively rather than litigate. Legal defense costs in a patent case alone routinely reach seven figures before trial.
The combination of FDA enforcement risk and Lilly litigation risk created an untenable liability profile for any vendor without deep legal resources. Removal from the catalog was the rational business response.
Evidence Ledger: Claims and Their Basis
| Claim | Best Evidence Type | Direction | Confidence |
|---|---|---|---|
| Tirzepatide is an FDA-approved drug (Mounjaro, Zepbound) | FDA NDA approval records (NDA 215866, NDA 217806) | Confirmed | High |
| Selling an approved drug outside the approved chain violates FDCA Section 301 | Statutory text, FDA enforcement precedent | Confirmed | High |
| FDA declared tirzepatide shortage resolved in December 2024 | FDA drug shortage database update, Federal Register | Confirmed | High |
| Eli Lilly filed patent suits against compounding pharmacies | Federal court dockets, trade press reporting (2024) | Confirmed | High |
| Research chemical vendors were never within the 503A/503B shortage exemption | DQSA statutory text, 21 U.S.C. 503A conditions | Confirmed | High |
| Peptide Sciences received a direct cease-and-desist from Lilly specifically | No public record found | Unknown | Very Low |
| Research-vendor tirzepatide products pose sterility and endotoxin risks | Analytical chemistry literature on unregulated peptide products; FDA warning letters | Plausible risk, not quantified for this specific vendor | Moderate |
What Most Pages Get Wrong About "Research Use Only" Labels
Many commodity blog posts imply that stamping "not for human use" or "research purposes only" on a vial of tirzepatide creates a legal safe harbor. It does not. The FDA has stated explicitly in multiple warning letters (including letters to GLP-1 peptide vendors in 2023 and 2024) that RUO labeling on an approved drug does not exempt the product from FDCA requirements.
The FDA evaluates the "intended use" of a product, and intended use is determined by the totality of circumstances: marketing language, customer base, website context, and the realistic understanding of who is buying and why. A vendor selling tirzepatide in injectable-ready vials with dosing guidance to fitness and weight-loss communities cannot credibly claim the product is not intended for human use.
This is why Peptide Sciences and similar vendors faced genuine legal exposure, not just theoretical risk.
How the Chemistry and Formulation Raised Additional Red Flags
Tirzepatide's approved formulation (Mounjaro, Zepbound) is a sterile, pH-buffered, subcutaneous injection using a specific excipient system developed and validated by Eli Lilly. The peptide itself is 39 amino acids with a C18 fatty acid chain attached at lysine-26, which is responsible for its albumin binding and extended half-life of approximately five days in humans.
Replicating this formulation precisely requires validated synthesis, fatty acid conjugation chemistry, and sterile fill-finish under cGMP conditions. A lyophilized research powder in a vial lacks the validated fatty acid conjugation confirmation, the sterility assurance testing, the endotoxin testing to USP requirements, and the osmolality and pH validation of the approved product.
Why does this matter practically? An injectable peptide reconstituted in bacteriostatic water and injected subcutaneously with none of those assurances carries real infection and inflammatory risk, independent of any regulatory question. The chemistry of the molecule itself (a large, fatty-acid-conjugated peptide) makes impurity profiling especially important because small synthesis byproducts from incomplete fatty acid conjugation can be immunogenic.
The FDA's concern is not abstract. The agency has documented cases of contaminated compounded GLP-1 products causing adverse events, and that enforcement record informed its decision-making around the shortage exemption closure.
Honest Comparison: Research Vendor vs. Licensed Pharmacy vs. Compounding Pharmacy
| Factor | Research Chemical Vendor | 503B Compounding Pharmacy | Licensed Retail Pharmacy (Brand) |
|---|---|---|---|
| Legal status for human use (post-shortage) | Not legal | Not legal (shortage window closed) | Legal with valid prescription |
| FDA oversight | None | Registered, inspected | Full NDA oversight |
| Sterility testing | Not required, rarely done | Required under USP 797 | Full cGMP batch release testing |
| Identity and purity confirmation | Variable; COA quality inconsistent | Required with defined specs | NDA-validated release testing |
| Fatty acid conjugation verified | Rarely confirmed by vendor COA | Should be; not always published | Yes, validated |
| Cost (approximate) | Lowest | Lower than brand | Highest (list price without insurance) |
| Endotoxin testing | Not standard | Required under USP 85 | Yes |
The research vendor wins only on cost. It loses on every quality and safety dimension. That is not a close call.
Operational Guide: How to Read a COA and What It Tells You
If you are evaluating any peptide product, including tirzepatide alternatives, understanding a certificate of analysis is essential. Here is what a COA should contain and what gaps reveal about a vendor:
Purity method and value. A credible COA states the analytical method (typically HPLC with UV detection, ideally also LC-MS/MS) and reports purity as a percentage. For a GLP-1 class peptide, less than 98 percent purity by HPLC should raise concern. A COA that states only "greater than 95 percent" with no method is essentially unfalsifiable.
Identity confirmation. For tirzepatide specifically, identity requires mass spectrometry confirming the molecular weight of the intact conjugated peptide. The theoretical molecular weight of tirzepatide free base is approximately 4813 Da. A COA that reports only an HPLC trace without mass confirmation cannot confirm the fatty acid conjugation was successful.
Endotoxin testing. Any peptide intended for injection must report an endotoxin value from a Limulus Amebocyte Lysate (LAL) test or equivalent. Most research vendor COAs omit this entirely. Its absence means you have no data on pyrogen load.
Who ran the test. The COA should name the testing laboratory. "In-house testing" by the vendor is a conflict of interest with no independent verification. A named third-party accredited lab (ISO 17025 accreditation) carries substantially more credibility.
What a COA cannot tell you. Even a perfect COA covers only the specific batch tested. It cannot confirm sterile fill conditions, proper storage during shipping, or that the product will remain stable in your hands. For injectable peptides, COA data is necessary but not sufficient to establish safety.
FAQ
Why did Peptide Sciences stop selling tirzepatide?
Peptide Sciences removed tirzepatide from its catalog primarily because tirzepatide is an FDA-approved drug protected by Eli Lilly patents, and selling it without regulatory authorization exposes a vendor to serious federal legal liability under the FDCA and patent infringement statutes. The closure of the shortage-based compounding window in December 2024 eliminated the last arguable legal gray zone.
Is tirzepatide legal to sell as a research chemical?
No. Tirzepatide is an approved new drug, not an unscheduled novel compound. Selling it outside the pharmacy or licensed compounding pathway violates the Federal Food, Drug, and Cosmetic Act regardless of any "research use only" label.
When did tirzepatide get FDA approval and why does that matter?
Tirzepatide received FDA approval for type 2 diabetes (Mounjaro) in May 2022 and for chronic weight management (Zepbound) in November 2023. Once a molecule is an approved drug, the "research chemical" classification no longer shields vendors from FDCA enforcement.
Did Eli Lilly send cease-and-desist letters to research peptide vendors?
Eli Lilly has pursued legal action against compounding pharmacies and has publicly stated it will defend its intellectual property. While specific letters to individual research chemical vendors are not all publicly documented, the patent and trade-secret exposure is the same legal risk regardless of company size.
Can compounding pharmacies still make tirzepatide?
The FDA declared tirzepatide no longer in shortage in December 2024, which ended the shortage-based compounding exemption for most 503A and 503B compounders. Some 503B outsourcing facilities had additional compliance time to wind down, but the general compounding window is now closed.
What is the difference between a research chemical vendor and a 503B compounding pharmacy?
A 503B outsourcing facility is FDA-registered, inspected, and may compound approved drugs under specific shortage or clinical conditions. A research chemical vendor is none of those things. The two categories carry entirely different legal standing and oversight.
Where can I now legitimately obtain tirzepatide?
Branded Mounjaro or Zepbound from a licensed pharmacy with a valid prescription is the only legally compliant path in the United States as of mid-2025. Telehealth prescribers can issue legitimate prescriptions that pharmacies fill.
How do I know if a tirzepatide product from an online vendor is safe?
You largely cannot verify safety without a certificate of analysis from an accredited third-party lab, and even then the sterility, endotoxin, and particulate standards required for injectable use are not routinely met by research chemical suppliers. The risk is substantial and real.
Did other research peptide companies also stop selling tirzepatide?
Yes. Multiple prominent research chemical vendors removed tirzepatide from their catalogs following FDA guidance, Eli Lilly legal pressure, and the closure of the shortage-based compounding window in late 2024. This was an industry-wide response to the same legal reality.
Is semaglutide in the same regulatory situation as tirzepatide?
Semaglutide (Ozempic, Wegovy) is also an FDA-approved drug with identical FDCA exposure. The FDA similarly declared semaglutide shortages resolved, ending most compounding exemptions. The legal landscape is parallel.
What should researchers who used Peptide Sciences tirzepatide do now?
If genuine preclinical research is the goal, tirzepatide is available through licensed API suppliers under proper research agreements. For clinical or personal use, a licensed prescriber and dispensing pharmacy is the only appropriate and legal path.
Sources
- U.S. Food and Drug Administration. "FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes." FDA News Release, May 13, 2022. (Mounjaro NDA 215866 approval)
- U.S. Food and Drug Administration. "FDA Approves New Medication for Chronic Weight Management." FDA News Release, November 8, 2023. (Zepbound NDA 217806 approval)
- U.S. Food and Drug Administration. "Drug Shortages: Tirzepatide." FDA Drug Shortages Database. Updated December 2024. (shortage resolution determination)
- U.S. Food and Drug Administration. "Compounding and the FDA: Questions and Answers." FDA Guidance, updated 2024. (503A and 503B framework)
- Drug Quality and Security Act of 2013, Pub. L. 113-54, 21 U.S.C. 503A, 503B. (compounding legal framework)
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301 et seq. (prohibited acts, drug definition at Section 321)
- 35 U.S.C. 271. (patent infringement statute)
- U.S. Food and Drug Administration. Warning letters to compounding pharmacies regarding GLP-1 products, 2023 to 2025. (publicly posted on FDA.gov warning letter database)
- Eli Lilly and Company v. various compounding pharmacies. Federal court filings, 2024. (patent enforcement actions; accessible through PACER federal court database)
- Coskun T, Sloop KW, Loghin C, et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus." Molecular Metabolism. 2018;18:3-14. (tirzepatide mechanism, amino acid sequence, fatty acid conjugation chemistry)
- U.S. Pharmacopeia. USP 797 Pharmaceutical Compounding: Sterile Preparations. (sterility standards referenced in the compounding comparison)
- U.S. Pharmacopeia. USP 85 Bacterial Endotoxins Test. (endotoxin testing standard referenced in COA guide)
Related peptide guides
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →